reports
Info Edge (India) Limited: 1 director
A director at Info Edge (India) Limited sold 120,000 shares at 1,103.718INR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Virtuix to Ring the Nasdaq Closing Bell on Wednesday, March 4, 2026
Virtuix to Ring the Nasdaq Closing Bell on Wednesday, March 4, 2026 Bell Ringing to Commemorate the Company’s Nasdaq Listing and Debut as a Public Company AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality systems, today announced the Company will ring the closing bell at the Nasdaq MarketSite in Times Square, New York on Wednesday, March 4, 2026. “Ringing the Nasdaq Closing Bell is a proud milestone for our team and a meaningful moment for our shareholders,” said Jan Goetgeluk, Chief Executive Officer of Virt...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 19 February 2026
19th February 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: N...
- ARM Research
January 2026 Inflation Report | Inflation Hits Lowest Since 2020
January’s inflation figures did more than surprise the market , they made history. Headline inflation fell to its lowest level since November 2020, food inflation slipped into single digit territory for the first time in 11 years, and the month recorded the sharpest contraction in food prices on record. These figures reflect a combination of stable exchange rates, lower fuel prices, and a moderation in post-festive demand following December 2025’s peak.
Jeffs' Brands: KeepZone AI Enters into Distribution Agreement with Ass...
Jeffs' Brands: KeepZone AI Enters into Distribution Agreement with Assac Networks to Distribute Cybersecurity Software Tel Aviv, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence (“AI”) – driven solutions, today announced that its wholly-owned subsidiary, KeepZone AI Inc. ("KeepZone "), has entered into a distribution agreement (the “Agreement”) with Assac Networ...
Recording of AB Akola Group Investor Webinar Presenting the 6-Month Un...
Recording of AB Akola Group Investor Webinar Presenting the 6-Month Unaudited Results for the 2025/2026 Financial Year On 19 February 2026, AB Akola Group held an investor webinar, where the company's Deputy CEO for Finance and Investments Mažvydas Šileika presented the financial results for the 6 months of the 2025/2026 financial year. The recording of the webinar is available on Nasdaq’s YouTube account: Link to the presentation demonstrated at the webinar: For more information: Mažvydas ŠileikaDeputy CEO for Finance and Investments of AB Akola GroupE-mail Mob.
AB Akola group 2025-2026 finansinių metų 6 mėnesių neaudituotų veiklos...
AB Akola group 2025-2026 finansinių metų 6 mėnesių neaudituotų veiklos rezultatų pristatymo internetiniame seminare įrašas 2026 m. vasario 19 d. vyko AB Akola group internetinis seminaras, kuriame įmonės generalinio direktoriaus pavaduotojas finansams ir investicijoms Mažvydas Šileika pristatė 2025–2026 finansinių metų 6 mėnesių veiklos rezultatus. Seminaro įrašą (anglų kalba) galima pasižiūrėti „Nasdaq“ YouTube paskyroje čia: Nuoroda į rodytą prezentaciją (anglų kalba): Papildomą informaciją suteiks: Mažvydas ŠileikaAB Akola group generalinio direktoriaus pavaduotojas finansams ir in...
BrainsWay Announces New Minority-Stake Investment in Canadian Provider...
BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc. BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarte...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates. To join a webcast of the call, please visit this . To join the teleconfe...
DT Midstream Reports Record 2025 Results; Raises Dividend and Increase...
DT Midstream Reports Record 2025 Results; Raises Dividend and Increases Project Backlog by 50% Full year 2025 Adjusted EBITDA of $1.138 billion, a 17% increase from 2024Increased dividend by 7%Announced final investment decision on two pipeline projects DETROIT, Feb. 19, 2026 (GLOBE NEWSWIRE) -- DT Midstream, Inc. (NYSE: DTM) today announced fourth quarter 2025 reported net income of $111 million, or $1.08 per diluted share. For the fourth quarter of 2025, Operating Earnings were also $111 million, or $1.08 per diluted share. Adjusted EBITDA for the quarter was $293 million. Full year 2...
Praxis Precision Medicines Provides Corporate Update and Reports Fourt...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026 Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting Cash and investments of...
ZenaTech’s ZenaDrone Subsidiary Initiates Green UAS Application for Ze...
ZenaTech’s ZenaDrone Subsidiary Initiates Green UAS Application for ZenaDrone 1000 to Strengthen U.S. Defense and Government Procurement Prospects VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces that its ZenaDrone subsidiary has formally initiated the Green UAS (Uncrewed Aircraft System) certification application process for its ZenaDr...
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 24,600 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incen...
Bombardier Announces Notice of Redemption for All Remaining Outstandin...
Bombardier Announces Notice of Redemption for All Remaining Outstanding 6.000% Senior Notes due 2028 MONTRÉAL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has issued a notice of redemption (the “Notice of Redemption”) for all of its remaining outstanding 6.000% Senior Notes due 2028, in an aggregate principal amount of US$250,000,000 (the “2028 Notes”). As set forth in the Notice of Redemption, the redemption date is March 6, 2026, and the redemption price for the 2028 Notes is 100% of the principal amount redeemed, plus accrued and unpaid inte...
Bombardier annonce un avis de rachat visant la totalité de ses billets...
Bombardier annonce un avis de rachat visant la totalité de ses billets de premier rang 6,000 % échéant en 2028 toujours en circulation MONTRÉAL, 19 févr. 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (« Bombardier ») a annoncé aujourd’hui l’émission d’un avis de rachat (l’« avis de rachat ») visant la totalité de ses billets de premier rang 6,000 % échéant en 2028 toujours en circulation d’un montant en capital global de 250 000 000 $ US (les « billets échéant en 2028 »). Comme il est indiqué dans l’avis de rachat, la date de rachat est fixée au 6 mars 2026 et le prix de rachat pour ces billet...
Trex Innovations Earn Top Industry and Global Design Honors
Trex Innovations Earn Top Industry and Global Design Honors Select® Decking and Signature® X-Series™ Railing recognized for performance and versatility WINCHESTER, Va., Feb. 19, 2026 (GLOBE NEWSWIRE) -- For more than 30 years, [NYSE:TREX] has set the standard for innovation in wood-alternative decking and railing with products Performance-Engineered™ for life outdoors. That legacy continues with new industry recognition: Pro Builder named Trex Select® Decking a , while Trex Signature® X-Series™ Railing earned top honors in the global . “Starting with the invention of composite deckin...
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLO...
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options Pre-clinical analysis of ti...
Laureate Education Reports Financial Results for the Fourth Quarter an...
Laureate Education Reports Financial Results for the Fourth Quarter and Full-Year 2025 and Provides 2026 Outlook Company Announces $150 Million Increase in Share Repurchase Authorization MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Highlights (compared to fourth quarter 2024): On a reported basis, revenue increased 28% to $541.4 million. On an organic constant c...
FuelCell Energy Releases 2025 Annual and Sustainability Reports
FuelCell Energy Releases 2025 Annual and Sustainability Reports DANBURY, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: FCEL) today released its 2025 Annual Report and 2025 Sustainability Report. Together, the reports detail the company’s financial and operational performance for fiscal year 2025 and its continued progress toward its long-term focus on distributed generation, disciplined growth, manufacturing scale, and profitability while advancing sustainability through innovation and clean energy technologies. The 2025 Annual Report Highlights Backlog increased to $1.19 billion ...
NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 an...
NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals NEWPORT BEACH, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences, Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the filing of ten (10) new U.S. patent applications expanding its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed to encourage animals to grow new muscle and increase muscle weight r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.